Thursday, May 28, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result

ITM Power’s £86.5m Gigafactory Bet: From Losses to a NATO-Fueled Growth Trajectory

Rodolfo Hanigan by Rodolfo Hanigan
May 28, 2026
in Uncategorized
0
ITM Power Stock
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

A British electrolyzer maker with a market value that has outpaced every analyst price target has just secured the financial firepower to build a fully automated production line. ITM Power is raising £86.5 million—half through an equity injection from Great British Energy, half via a government grant—to bring its next-generation “Chronos” stack to scale. The money will fund a one-gigawatt factory in the UK, a facility the company hopes will turn it from a loss-making engineering shop into a high-volume manufacturer.

The capital injection breaks down as £40 million in new equity from Great British Energy, the state-backed investment vehicle, and £46.5 million from the UK Department for Energy Security and Net Zero as a direct grant. ITM expects to take a final investment decision on the Chronos project in June. Berenberg, which upgraded its target from 100p to 110p, described the funding as a “significant platform” for long-term growth—though that target sits well below the current share price of 194.70p.

Alongside the factory financing, ITM has lifted its revenue guidance for the current fiscal year to £40–43 million from a prior range of £35–40 million. First‑half revenue hit a record £18 million, up 16% year on year. Losses are narrowing too: the adjusted EBITDA deficit shrank to £11.9 million from £16.8 million a year earlier. The order book stands at £152 million, with 71% of contracts classified as high quality. Morgan Stanley now expects ITM to reach EBITDA breakeven in fiscal 2028—one year earlier than previously forecast.

The balance sheet gives management room to execute. After the capital raise, ITM expects cash on hand of between £210 million and £215 million. With no debt on the books, analysts see no need for additional equity this decade. That war chest is earmarked for the Chronos factory and for scaling delivery on large projects, notably the 120‑MW Humber H2ub plant that Uniper is developing. ITM will supply six 20‑MW Poseidon modules for the first phase.

Should investors sell immediately? Or is it worth buying ITM Power?

Perhaps the most striking shift in ITM’s story is its move into defense. The company has teamed up with Rheinmetall on Project Giga PtX, a plan to build several hundred decentralised synthetic fuel plants across Europe, each with up to 50 MW of electrolysis capacity, to supply NATO forces. CEO Dennis Schulz frames the partnership as a fusion of the energy transition and national security. Arms‑focused contracts offer stable, policy‑shielded demand that does not rely on the fickle civilian hydrogen market.

The analyst community is scrambling to keep up with the stock’s rally. Jefferies recently lifted its price target from 115p to 200p, maintaining a buy rating. Morgan Stanley rates the shares overweight with a 170p target. Berenberg sticks with buy but sees fair value at only 110p. The divergence between the current price and most forecasts does not automatically signal overvaluation. Strategists point to a dense calendar of catalysts that could justify the premium—or widen the gap.

June is laden with potential triggers. The Chronos final investment decision is expected within weeks. The UK government’s Hydrogen Allocation Round 2 results are due, which could allocate subsidy contracts to ITM’s projects. Uniper’s Humber H2ub must reach its own final investment decision to convert the Poseidon order into hard revenue. And on 29 May, MSCI will rebalance its indexes, a process that forces institutional funds to adjust holdings and can create a sudden wave of buying if ITM’s weighting changes.

ITM Power has crossed from the phase of promise to the phase of execution. It has the factory plan, the order book, the cash—and a new customer in the NATO machinery. The next sixty days will show whether the share price is running ahead of reality or merely pricing in what the analysts have yet to fully see.

Ad

ITM Power Stock: Buy or Sell?! New ITM Power Analysis from May 28 delivers the answer:

The latest ITM Power figures speak for themselves: Urgent action needed for ITM Power investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 28.

ITM Power: Buy or sell? Read more here...

Tags: ITM Power
Rodolfo Hanigan

Rodolfo Hanigan

Related Posts

Assembly Biosciences Stock
Analysis

Assembly Biosciences Strengthens Pipeline and Balance Sheet After $115M Upsized Raise

May 28, 2026
The Platform Group Stock
E-Commerce

The Platform Group’s EBITDA Surges 37%, but a Perfect Storm of Headwinds Keeps the Stock in the Doldrums

May 28, 2026
Adidas Stock
Consumer & Luxury

Adidas Transforms into a Data Powerhouse as World Cup Orders Pour In

May 28, 2026
Next Post
KNDS Stock

KNDS Reports €661m Operating Profit and €33bn Backlog as Dual Frankfurt-Paris IPO Nears Final Hurdle

DroneShield Stock

DroneShield Heads Into AGM with Record Backlog and a Proxy Adviser’s Rebuke

Palantir Stock

Palantir's Developer Console Upgrade Arrives as Rivals Copy Its Playbook and CEO Sells $54M in Stock

Recommended

Broker business

Unveiling the Future of Economic Freedom: Trends in Parallel Economy Conventions

2 years ago
Neutra Stock

Shifting Focus: How Neutra is Pivoting to Clinical Trial Management

2 months ago
TSMC Stock

TSMC Stock Surges on Dual Catalysts: Export License and Next-Gen Chip Progress

5 months ago
Lockheed Stock

Lockheed Martin Navigates Expansion and Legal Challenges

9 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Ubtech Robotics Bolsters Korean Alliance and Boardroom Grip Amid Humanoid Revenue Surge

Ferrexpo’s Double Squeeze: A Kyiv Court Battle and a $100 Million Funding Logjam Keep Shares Frozen

Refined Energy’s Uranium Push Gains Urgency as Board Shuffles and Drilling Progresses

AMD’s Trillion-Dollar Ambition Meets the $500 Ceiling: Strong Earnings Can’t Silence Profit-Takers

Navitas Semiconductor: A $6.7 Billion Bet on AI Data Centers With Only $8.6 Million in Quarterly Sales

Eli Lilly’s Two-Front Victory: A Trillion-Dollar Valuation and a Pharmacy Benefit Win Reshape the Obesity Landscape

Trending

Assembly Biosciences Stock
Analysis

Assembly Biosciences Strengthens Pipeline and Balance Sheet After $115M Upsized Raise

by SiterGedge
May 28, 2026
0

Assembly Biosciences has emerged from the EASL Congress in Barcelona with more than just data. The biotech...

The Platform Group Stock

The Platform Group’s EBITDA Surges 37%, but a Perfect Storm of Headwinds Keeps the Stock in the Doldrums

May 28, 2026
Adidas Stock

Adidas Transforms into a Data Powerhouse as World Cup Orders Pour In

May 28, 2026
Ubtech Robotics Stock

Ubtech Robotics Bolsters Korean Alliance and Boardroom Grip Amid Humanoid Revenue Surge

May 28, 2026
Ferrexpo Stock

Ferrexpo’s Double Squeeze: A Kyiv Court Battle and a $100 Million Funding Logjam Keep Shares Frozen

May 28, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Assembly Biosciences Strengthens Pipeline and Balance Sheet After $115M Upsized Raise
  • The Platform Group’s EBITDA Surges 37%, but a Perfect Storm of Headwinds Keeps the Stock in the Doldrums
  • Adidas Transforms into a Data Powerhouse as World Cup Orders Pour In

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com